A Study of ZW171 in Participants with Advanced or Metastatic Mesothelin Expressing Cancers
This early-stage study, called Phase 1, is looking into a new treatment called ZW171. It's for people whose cancers, such as advanced ovarian, non-small cell lung (NSCLC), or pancreatic cancer, have spread or are difficult to treat. These cancers also need to have a specific protein called mesothelin. The main goal is to understand if ZW171 is safe to use in people and how their bodies react to it. This is usually the first time a new medicine is given to human volunteers after being tested in labs. Researchers want to learn more about its effects, both good and bad, to see if it could be a helpful treatment in the future. It's an important step in developing new cancer medicines.
At a glance
What is this study about?
This research study is called 'A Study of ZW171 in Participants with Advanced or Metastatic Mesothelin Expressing Cancers'. In simple terms, it means scientists are testing a new medicine, which they've named ZW171, in people who have certain types of cancer that have spread in their body. These include advanced ovarian cancer, specific types of lung cancer (called NSCLC), pancreatic cancer, and other similar cancers. A key point is that these cancers must have a particular protein on their surface called mesothelin. Think of mesothelin as a kind of flag on the cancer cells that the new medicine might be designed to target.
This study is in its very first stage of testing in humans, known as 'Phase 1' or 'Human Pharmacology'. This means it's one of the first times this new medicine, ZW171, is being given to people. The main purpose at this early stage is to find out if the medicine is safe, what the right dose might be, and how the body reacts to it. It's not primarily about seeing if it cures the cancer at this point, but rather about gathering crucial safety information to decide if it's promising enough to continue testing in larger studies.
Studying new medicines like ZW171 is really important because it helps doctors and scientists discover better ways to treat cancer in the future. By understanding how new treatments work and what their effects are, researchers can make progress in developing new options for people whose current treatments might not be working as well as hoped. Every new medicine goes through these careful steps to ensure it is as safe and effective as possible.
Key takeaways
- This is an early-stage study testing a new medicine called ZW171 for the first time in people.
- It's for specific advanced or spreading cancers that have a protein called mesothelin.
- The main aim is to check the medicine's safety and how the body reacts to it.
- Participants will have regular check-ups and follow-up.
- It’s an important step in finding new cancer treatments.
- You can stop participating at any time.
Who may be eligible?
To join this study, people generally need to be 18 years or older. There isn't an upper age limit, meaning older adults can also be considered.
The study is open to both men and women, so your gender doesn't prevent you from taking part if you meet other criteria.
Crucially, you would need to have certain types of cancer that have either spread from where they started (metastatic) or are advanced. These include ovarian cancer, a specific kind of lung cancer (non-small cell lung cancer), or pancreatic cancer. Your cancer would also need to show specific markers, in this case, a protein called mesothelin. The research team will do tests to check if your cancer has this marker. They will also look at your overall health to make sure joining the study is safe for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Am I 18 years old or older?
- Do I have advanced or spreading ovarian, lung (NSCLC), or pancreatic cancer, or a similar cancer?
- Have my doctors confirmed my cancer has the mesothelin protein?
- Am I generally well enough to take part in a clinical study?
What does participation involve?
If you decide to take part, you would have regular visits to the clinic. These visits would involve check-ups, blood tests, and possibly other tests like scans to monitor your health and how the medicine is affecting your body and the cancer. You would receive the study medicine, ZW171, according to a schedule set by the doctors. The duration of your participation would depend on how your body responds to the treatment and the study plan, but it will be made clear to you before you start. There will also be follow-up appointments after you stop taking the medicine to ensure your well-being is monitored.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What does 'Phase 1' mean for this study?
Phase 1 means this is an early study where the new medicine, ZW171, is given to people for the first time. The main goal is to check how safe it is and how the body handles it, rather than focusing on its effectiveness just yet.
What special protein do my cancer cells need to have?
Your cancer cells would need to have a specific protein called mesothelin for you to be eligible for this study. The study doctors will test for this.
Will this medicine cure my cancer?
It's too early to say if ZW171 will cure cancer. This is a very early study focused on safety, but researchers hope it could lead to new, effective treatments in the future.
How long would I be in the study?
The exact length of time you'd be in the study can vary. The doctors will discuss the expected duration with you, including active treatment and follow-up periods.
Can I leave the study if I change my mind?
Yes, you can leave the study at any time, for any reason, without it affecting your regular medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.